An assessment of neuronal calcium sensor-1 and response to neoadjuvant chemotherapy in breast cancer patients

Lauren M. Moore; Rachel Wilkinson; Mehmet Altan; Maria Toki; Daniel E. Carvajal-Hausdorf; John McGuire; Barbara E. Ehrlich; David L. Rimm

doi:10.1038/s41523-018-0057-7

An assessment of neuronal calcium sensor-1 and response to neoadjuvant chemotherapy in breast cancer patients

Lauren M. Moore, Rachel Wilkinson, Mehmet Altan, Maria Toki, Daniel E. Carvajal-Hausdorf, John McGuire, Barbara E. Ehrlich, David L. Rimm

Thoracic Head & Neck Medical Oncology

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

Neuronal calcium sensor-1 (NCS-1) has been identified as a binding partner of the taxane, paclitaxel. Our previous study showed that overexpression of NCS-1 increased the efficacy of paclitaxel in vitro, but was associated with poor clinical outcome. Here, we determine if NCS-1 expression is associated with pathological complete response (pCR) to taxane-based neoadjuvant chemotherapy in 105 pre-treatment breast cancer biopsies. Elevated expression of NCS-1 was found to be positively associated with pCR. These results suggest that NCS-1 may be a predictive biomarker for response to taxane-based neoadjuvant chemotherapy in breast cancer.

Original language	English (US)
Article number	6
Journal	npj Breast Cancer
Volume	4
Issue number	1
DOIs	https://doi.org/10.1038/s41523-018-0057-7
State	Published - Dec 1 2018

ASJC Scopus subject areas

Oncology
Radiology Nuclear Medicine and imaging
Pharmacology (medical)

Access to Document

10.1038/s41523-018-0057-7

Cite this

@article{5026298c3da3414580c1e05ec389db79,

title = "An assessment of neuronal calcium sensor-1 and response to neoadjuvant chemotherapy in breast cancer patients",

abstract = "Neuronal calcium sensor-1 (NCS-1) has been identified as a binding partner of the taxane, paclitaxel. Our previous study showed that overexpression of NCS-1 increased the efficacy of paclitaxel in vitro, but was associated with poor clinical outcome. Here, we determine if NCS-1 expression is associated with pathological complete response (pCR) to taxane-based neoadjuvant chemotherapy in 105 pre-treatment breast cancer biopsies. Elevated expression of NCS-1 was found to be positively associated with pCR. These results suggest that NCS-1 may be a predictive biomarker for response to taxane-based neoadjuvant chemotherapy in breast cancer.",

author = "Moore, {Lauren M.} and Rachel Wilkinson and Mehmet Altan and Maria Toki and Carvajal-Hausdorf, {Daniel E.} and John McGuire and Ehrlich, {Barbara E.} and Rimm, {David L.}",

note = "Publisher Copyright: {\textcopyright} 2018, The Author(s).",

year = "2018",

month = dec,

day = "1",

doi = "10.1038/s41523-018-0057-7",

language = "English (US)",

volume = "4",

journal = "npj Breast Cancer",

issn = "2374-4677",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - An assessment of neuronal calcium sensor-1 and response to neoadjuvant chemotherapy in breast cancer patients

AU - Moore, Lauren M.

AU - Wilkinson, Rachel

AU - Altan, Mehmet

AU - Toki, Maria

AU - Carvajal-Hausdorf, Daniel E.

AU - McGuire, John

AU - Ehrlich, Barbara E.

AU - Rimm, David L.

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Neuronal calcium sensor-1 (NCS-1) has been identified as a binding partner of the taxane, paclitaxel. Our previous study showed that overexpression of NCS-1 increased the efficacy of paclitaxel in vitro, but was associated with poor clinical outcome. Here, we determine if NCS-1 expression is associated with pathological complete response (pCR) to taxane-based neoadjuvant chemotherapy in 105 pre-treatment breast cancer biopsies. Elevated expression of NCS-1 was found to be positively associated with pCR. These results suggest that NCS-1 may be a predictive biomarker for response to taxane-based neoadjuvant chemotherapy in breast cancer.

AB - Neuronal calcium sensor-1 (NCS-1) has been identified as a binding partner of the taxane, paclitaxel. Our previous study showed that overexpression of NCS-1 increased the efficacy of paclitaxel in vitro, but was associated with poor clinical outcome. Here, we determine if NCS-1 expression is associated with pathological complete response (pCR) to taxane-based neoadjuvant chemotherapy in 105 pre-treatment breast cancer biopsies. Elevated expression of NCS-1 was found to be positively associated with pCR. These results suggest that NCS-1 may be a predictive biomarker for response to taxane-based neoadjuvant chemotherapy in breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=85056695225&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056695225&partnerID=8YFLogxK

U2 - 10.1038/s41523-018-0057-7

DO - 10.1038/s41523-018-0057-7

M3 - Article

C2 - 29560416

AN - SCOPUS:85056695225

SN - 2374-4677

VL - 4

JO - npj Breast Cancer

JF - npj Breast Cancer

IS - 1

M1 - 6

ER -

An assessment of neuronal calcium sensor-1 and response to neoadjuvant chemotherapy in breast cancer patients

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this